|
| No. | Product Name | Grade | Drug Category | Regulatory Filings | |||
|---|---|---|---|---|---|---|---|
| CEP/EDMF | DMF/ WC | ||||||
| 1 | Acamprosate Calcium | BP/EP/USP | Alcohol Abstinence | CEP 2026-166-P01 | KDMF* | ||
| 2 | Aciclovir | BP/EP/USP | Antivirals | * | |||
| 3 | Apixaban | IH | Anti-coagulant | * | KDMF, WC | ||
| 4 | Aprepitant | USP | Antiemetic | ||||
| 5 | Bempedoic Acid | IH | Antihyperlipidemic | KDMF*, CADIFA* | |||
| 6 | Brivaracetam | IH/EP | Anticonvulsant | * | |||
| 7 | Carbocistine | EP | Mucolytic | CEP 2025-156 - Rev 00 | WC | ||
| 8 | Cariprazine | IH | Anti-psychotic | ||||
| 9 | Dapagliflozin Propanediol | EP/IH/USP | Anti Diabetic | FI/PL: DRL-RLE.4003.69.2026, UK : 100984679 | AU*, WC | ||
| 10 | Dexlansoprazole | IH | Proton Pump Inhibitor (GERD) | * | WC | ||
| 11 | Edoxaban Tosylate Monohydrate | IH | Anti-coagulant | DE/LU : 2473647, UK : 2474440 | KDMF* | ||
| 12 | Eltrombopag Olamine | IH | Anti Thrombocytopenia | * | WC | ||
| 13 | Empagliflozin | IH | Anti Diabetic | UK : 100984652 | AU*, WC | ||
| 14 | Etoricoxib | IH | NSAID | ||||
| 15 | Febuxostat | IH | Anti Gout | * | KDMF*, WC | ||
| 16 | Fenofibrate | EP/USP | Antilipemic agent | ||||
| 17 | Iron Polymaltose | IH | Hematinic, Antianemics | * | |||
| 18 | Lisdexamfetamine Dimesylate | IH | Psychostimulant (ADHD) | * | CADIFA* | ||
| 19 | Mirabegron | IH/EP | Anticholinergic | CEP 2026-417-P01 | |||
| 20 | Quetiapine Fumarate | EP/USP | Anti-psychotic | CEP 2025-326-P01 | KDMF, CADIFA* | ||
| 21 | Rivaroxaban | USP/EP | Anti-coagulant | CEP 2025-240-Rev 00 | |||
| 22 | Vonoprazan Fumarate | IH | Anti ulcerant / GERD Treatment | ||||
* Planned in 2026-27, FI : Finland, PL : Poland, DE : Germany, UK : United Kingdom, AU : Australia, LU : Luxembourg, WC : Written Confirmation, KDMF : Korea DMF, CADIFA : Brazil DMF
All products are supported with DMF and Technical Package